This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Adherence of Stalevo, Entacapone and Levodopa

This study has been completed.
Information provided by:
South Glasgow University Hospitals NHS Trust Identifier:
First received: October 27, 2005
Last updated: May 22, 2008
Last verified: May 2008

To test if combining two antiparkinson drugs into a single tablet improves accuracy of medicine intake by the patient.

To test if patients with Parkinson's disease who take medicines at regular time intervals have smoother symptom control.

Parkinson's Disease

Study Type: Observational
Official Title: Study of Adherence of Stalevo, Entacapone and Levodopa

Resource links provided by NLM:

Further study details as provided by South Glasgow University Hospitals NHS Trust:

Estimated Enrollment: 14
Study Start Date: April 2005
Study Completion Date: July 2006

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients diagnosed with Parkinson's disease aged between 18 and 85 years fulfilling UK Brain Bank criteria.
  • Current levodopa therapy prescribed on a regular basis three or more times per day but requiring entacapone because of 'wearing off'
  • Able to manipulate electronic monitoring bottles and complete questionnaires

Exclusion Criteria:

  • Current use of compliance aid such that study participation would be detrimental to patient's adherence
  • Pregnancy or breast feeding
  • Excess alcohol (over 21 units per week for women and 28 units for men)
  • Mini mental state examination of less than 26.
  • Severe depression (Geriatric depression score over 20)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00245700

United Kingdom
Southern General Hospital
Glasgow, Scotland, United Kingdom, G51 4TF
Sponsors and Collaborators
South Glasgow University Hospitals NHS Trust
Principal Investigator: Donald G Grosset, MBChB, MD
  More Information

Responsible Party: Dr D Grosset, Southern General Hospital Identifier: NCT00245700     History of Changes
Other Study ID Numbers: R050017
Grant from Orion Pharma
Study First Received: October 27, 2005
Last Updated: May 22, 2008

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Catechol O-Methyltransferase Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017